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Crystal structure of the actin-binding region of utrophin reveals a
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Background: Utrophin is a large multidomain protein that belongs to a
superfamily of actin-binding proteins, which includes dystrophin, α-actinin,
β-spectrin, fimbrin, filamin and plectin. All the members of this family contain a
common actin-binding region at their N termini and perform a wide variety of
roles associated with the actin cytoskeleton. Utrophin is the autosomal
homologue of dystrophin, the protein defective in the X-linked Duchenne and
Becker muscular dystrophies, and upregulation of utrophin has been suggested
as a potential therapy for muscular dystrophy patients.
Results: The structure of the actin-binding region of utrophin, consisting of two
calponin-homology (CH) domains, has been solved at 3.0 Å resolution. It is
composed of an antiparallel dimer with each of the monomers being present in
an extended dumbell shape and the two CH domains being separated by a
long central helix. This extended conformation is in sharp contrast to the
compact monomer structure of the N-terminal actin-binding region of fimbrin. 
Conclusions: The crystal structure of the actin-binding region of utrophin
suggests that these actin-binding domains may be more flexible than was
previously thought and that this flexibility may allow domain reorganisation
and play a role in the actin-binding mechanism. Thus utrophin could possibly
bind to actin in an extended conformation so that the sites previously
identified as being important for actin binding may be directly involved in
this interaction.
Introduction
Utrophin is a 395 kDa multidomain cytoskeletal protein,
expressed ubiquitously in humans, which is a close homo-
logue of dystrophin, the 427 kDa protein defective in
Duchenne and Becker muscular dystrophies. Utrophin and
dystrophin are composed of three regions: an N-terminal
region that binds actin filaments [1], a large central region
consisting of 22 and 24 triple-helical coiled-coil repeats, in
utrophin and dystrophin, respectively [2], and a C-terminal
region with a series of sequence motifs such as EF-hand
putative calcium-binding regions, ZZ zinc-binding and
WW domains that are believed to interact with compo-
nents of a transmembrane glycoprotein complex [3]. This
transmembrane complex in turn interacts with the extra-
cellular matrix, completing a link between the actin
cytoskeleton and the extracellular matrix (see [4] for a
review). This link is believed to be important in maintain-
ing the integrity of the cell membrane. Dystrophin is
thought to protect muscle from damage during contraction
and its absence results in myopathy. The precise role of
utrophin is less clear although it may have a similar func-
tion to dystrophin, as it can functionally replace dystrophin
in the dystrophin-deficient mdx mouse [5]. Utrophin may
also have a role in the organisation of distinct membrane
regions in both muscle and non-muscle cells [6,7], and it is
important in stabilisation of acetylcholine receptor clusters
at the neuromuscular junction [8].
The N-terminal actin-binding region of utrophin has
sequence similarity to regions in a diverse range of actin-
binding proteins including dystrophin, β-spectrin, α-actinin
and, more distantly, fimbrin. These ~240-residue actin-
binding regions are composed of two structurally equiva-
lent [9] but functionally distinct domains [10], which have
been called calponin-homology (CH) domains [11]. The
actin-binding regions have probably arisen by gene dupli-
cation of this 120-residue repeat found in a single copy in a
number of other proteins, including the smooth muscle
regulatory protein calponin [9,11]. Phylogenetic analysis of
proteins containing CH domains reveals that there is
greater similarity among the N-terminal CH domains
(CH1) or the C-terminal CH domains (CH2) in any of the
classes of actin-binding proteins than there is between the
CH1 and CH2 domains within the same actin-binding
protein [12–14]. The domains from fimbrin are the most
evolutionarily distant and can be regarded as separate sub-
types [12]. Although a number of proteins containing a
single CH domain are able to bind actin, individual CH
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domains isolated from these proteins are unable to bind
actin alone [10,15]. The complete actin-binding region
(CH1 and CH2 domains) of this superfamily of proteins
should thus be considered as the functional actin-
binding portion of these molecules. Within this region,
sequence comparisons and a variety of biochemical and
nuclear magnetic resonance (NMR) spectroscopy
approaches have identified three areas of sequence
(named actin-binding sites, ABSs) that have been impli-
cated in binding to actin, although their precise involve-
ment in binding still needs to be confirmed (discussed in
the review [16]).
The structures of the second CH domains (CH2) of spec-
trin [17] and utrophin [13] and of both CH domains of the
first actin-binding region of fimbrin [18] have been deter-
mined by X-ray crystallography. Here, we present the
3.0 Å structure of the actin-binding region of utrophin and
discuss how it differs from the structure of the equivalent
region in fimbrin [18].
Results and discussion
Utrophin domain structure
The structure of the N-terminal actin-binding region
(residues 28–261) of human utrophin was solved by multi-
ple wavelength anomalous dispersion and refined to 3.0 Å
resolution (Table 1; see the Materials and methods
section). It crystallises as an antiparallel dimer (Figure 1a)
with each CH1 domain being separated from the CH2
domain by a long central helix (α6A), forming a dumbell-
shaped molecule. Dimerisation brings CH1 from one mol-
ecule into close proximity with CH2 from the other
molecule in the dimer (Figure 1a).
The utrophin monomer with the helices labelled as in ref-
erence [13] is shown in Figure 1b and the electron density
of the linker helix α6A in Figure 1c. The CH1 domain
runs from the N terminus (Asp31) to Gln149 and the CH2
domain runs from Ser152 to Leu254 at the C terminus.
The structure of the CH2 domain in the dimer shows no
significant difference from the 2.0 Å resolution structure
of the isolated CH2 domain [13]. The CH1 domain also
has the expected secondary structure for a CH domain of
four main α helices (α1, α3, α4 and α6). It also has the
shorter α5 helix found in the structure of all CH domains
determined so far. As expected, the utrophin CH2 domain
is more similar to the spectrin CH2 domain than to the
utrophin CH1 domain (Figure 2a). Furthermore, the back-
bone of the utrophin CH1 domain resembles the fimbrin
CH1.1 domain (root mean square deviation [rmsd] for Cα
atoms is 2.2 Å) more than any of the solved CH2 domains
(rmsd Cα > 2.5 Å with any CH2 domain), particularly at
the start of helices α4 and α5, but differs from all other
CH domains in the region following α1 (Figure 2a). The
backbone immediately preceding α3 is similar in all
CH-domain structures. There is a short helical stretch, but
its geometry only satisfies automatic secondary structure
assignment programs as a 310 helix in utrophin CH2 (α2)
and fimbrin CH1.1. This is followed by a highly conserved
sharp turn caused by a conserved aspartate–glycine motif.
Utrophin dimer structure 
The dimeric organisation of utrophin contrasts with the
fimbrin actin-binding domain structure [18], which is a
compact monomer. The two CH domains in fimbrin fold
back on themselves to form a compact globular structure
whereas, although the same interface exists between the
CH domains in utrophin, this is achieved by an antiparal-
lel association of two utrophin molecules in the crystal.
The interface between CH1 and CH2 domains in fimbrin
is formed by α1 and α6 of CH1 and α6′ and the region
between α4′ and α5′ of CH2 [18]. In utrophin, these
regions are still involved in inter-CH domain interactions,
but they are found between the CH1 domain in one mol-
ecule and the CH2 domain of the other molecule in the
dimer. In addition, there are further interactions of the
α6A helices of the CH1 domains and the α1′ helices of
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Table 1
Data collection and refinement statistics.
Data sets (Å) λ1 (0.9000) λ2 (0.9795) λ3 (0.9809)
Remote Point of inflexion Peak
Resolution range (Å) 24–3.0 24–3.0 24–3.0
(final shell) (3.16–3.00) (3.16–3.00) (3.16–3.00)
Unique reflections 12,342 12,369 12,355
Completeness (%) 96.7 96.8 96.6 
(final shell) (97.2) (96.2) (96.3)
Redundancy 2.7 2.8 2.7
(final shell) (2.6) (2.4) (2.4)
Anomalous
completeness (%) 87.1 84.3 84.7
Rmerge 0.057 0.047 0.055
(final shell) (0.146) (0.140) (0.153)
Ranom 0.063 0.043 0.063
(final shell) (0.123) (0.118) (0.132)
Phasing power* (Å)
Isomorphous 
centric (acentric) 24–3.2 3.3 (3.5) 2.0 (4.5)
Anomalous 2.2 2.1 2.9
Figure of merit† 0.80/0.91
Refinement resolution (Å) 25–3.0
(final shell) (3.19–3.00)
R factor (final shell) 0.198 (0.300)
Rfree (final shell) 0.258 (0.354)
Rmsd
Bonds (Å) 0.007
Angles (°) 1.2
Average B factor
Mainchain 41.9
Sidechain 47.2
Water 25.1
Data were collected off a single crystal at three wavelengths round the
selenium absorption edge measured by fluorescence on Station BM14
of the ESRF using a Princeton charge-coupled device detector. Space
group is C2, a = 150.15 Å, b = 55.19 Å, c = 80.28 Å and β = 106.02°.
*Phasing power determined using the program SHARP [48]. †Figure of
merit before/after solvent flattening.
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Figure 1
Structure of the utrophin actin-binding
domain. (a) The utrophin actin-binding region
dimer, with chain A in red and chain B in blue
and with the CH2 domain on the right.
(b) Chain B of utrophin (residues 31–258)
with the N terminus and CH1 at the left and
the C terminus and CH2 to the right. Helices
are labelled as in [13]. The region
corresponding to actin-binding site ABS1
(CH1 α1) is in green, ABS2 (CH1 α5–α6) is
in blue and ABS3 (CH2 α1) is in red. Chain B
is in the same orientation as in (a). (c) Stereo
pair of the 2Fo–Fc electron density of region
α6A of the A chain contoured at 1σ. This is
the helix at the end of CH1 that links to CH2.
The selenomethionines are on the left
(seleniums in yellow). The figure was
produced using BOBSCRIPT [51].
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Structure
the CH2 domains that stabilise the dimer. The fimbrin
structure is similar to the composite of the CH1 from one
molecule and the CH2 of the other molecule in the
utrophin dimer (rmsd Cα 2.7 Å), as shown in Figure 2b. 
Three-dimensional domain swapping describes the preser-
vation of an interface between two domains in monomeric
and oligomeric forms of the same or related proteins (see
[19] for a review). Fimbrin and utrophin are an example of
this phenomenon, and support the idea that monomeric
utrophin observed in solution (see below) may adopt a
more compact, fimbrin-like conformation. The major
determinant of domain-swapped dimer formation is
thought to be the properties of the residues linking the
swapped domains, rather than the conserved interfaces
between them [19]. Thus the linker between domains
may be involved in forming stabilising contacts that favour
dimerisation. In the case of utrophin, there are extensive
contacts burying an area of 728 Å2 in the dimer that would
not be found in the monomer. For the monomer to fold
into a compact form, the linker between the CH domains
would need to be sufficiently long and flexible to allow the
chain to fold back on itself. The linker in fimbrin is thir-
teen residues longer and more flexible than in utrophin,
such that nine residues are not visible in the fimbrin
crystal structure [18]; this would probably favour formation
of a compact monomer. Inspection of the position of the
symmetry-related molecules rules out the possibility that
the CH1 and CH2 domains come from different chains in
fimbrin. In utrophin only two residues in molecule A (150
and 151) are not part of the regular secondary structure,
whereas in molecule B this is extended to six (148–153). A
modest level of unwinding of secondary structure would
be sufficient to allow monomer formation as the distance
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Figure 2
Similarity of CH domains of utrophin to other
structures. (a) Stereo pair of superimposed
α-carbon backbones for CH2 domains of
utrophin (red), spectrin (blue) [17], fimbrin
CH1.1 (purple) and fimbrin CH2.1 (green)
[18], and utrophin CH1 (yellow). The utrophin
sequence is numbered at every ten residues.
The superpositions were calculated on helices
α1, α3, α4 and α6 using LSQMAN [52].
(b) Stereo pair of the α-carbon backbone of
the dimer structure shown in Figure 1a
(rotated by 90° about the normal to the page);
chain A is in red and chain B is in blue.
Fimbrin (green) is superposed on the utrophin
CH1 domain of A and CH2 domain of B. The
red copy of the utrophin monomer is labelled
every 20 residues. The figure was produced
using BOBSCRIPT [51].
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Structure
from A147–B155 is only 8.4 Å. However, the clear elec-
tron-density maps in this region and the selenium sites at
methionines 140 and 144 in both chains preclude this
being the case in the utrophin crystals (Figure 1c). 
Gel-filtration studies on the utrophin actin-binding region
(residues 1–261) under a variety of salt conditions revealed
that it eluted after G-actin (Mr 43 kDa), consistent with it
being a ~30 kDa monomer in solution [1]. Furthermore,
more recent analytical ultracentrifugation and gel-filtration
studies indicate that the utrophin actin-binding region is a
monomer in solution with a molecular weight of 25 kDa
(CAM, unpublished results). Thus the crystal structures of
fimbrin and utrophin may represent two potential
extremes of conformation that can be adopted by this class
of actin-binding protein, with the monomer in the utrophin
structure representing the ‘open’ conformation and the
monomer in the fimbrin structure representing the ‘closed’
conformation. The open conformation observed in the
utrophin crystals is very similar to the two densities pre-
sumed to be the two CH domains of α-actinin as observed
by electron microscopy [20]. This suggests that the crystal
structure of utrophin in this conformation may be repre-
sentative of other members of this superfamily of actin-
binding proteins. 
Molecular interfaces
The utrophin crystal contains an interface made up of the
antiparallel association of CH1 and CH2 domains from dif-
ferent molecules. In the fimbrin crystal [18] there is a very
similar interface between the CH1 and CH2 domains
(Figure 2b), but from the same molecule. The interface
between the utrophin CH1 and CH2 domains in solution
may therefore be dynamic, exchanging between open and
closed states. The gap/volume index [21] of 2.7 for the
fimbrin region indicates that the fimbrin interface may be
dynamic [14]. However, omission of one contact between
amino acids 248 and 261 in the poorly modelled linker
between the CH1 and CH2 domains in fimbrin gives a
lower value that is similar to that for the utrophin interface
(1.8) and the value is less clearly from a dynamic interface.
The utrophin interface is more polar than that of fimbrin
and has more hydrogen bonds and salt bridges; these factors
are generally higher for dynamic interfaces [21]. However,
this type of analysis cannot clearly distinguish between
dynamic and static interfaces, as the ranges overlap.
There is some conservation of residues at the CH domain
interfaces in fimbrin and utrophin. In particular Trp40
and Trp128 in utrophin are conserved as Trp132 and
Trp232 in fimbrin, and Lys241 in utrophin as Lys364 in
fimbrin. The details of the interfaces differ, however, as
neither of the two salt bridges in fimbrin are found in
utrophin. One is maintained as a hydrogen bond but the
change of Glu124 in fimbrin to Gln33 in utrophin
removes one of the charges, and the acidic group in
Glu253, equivalent to the second salt bridge in fimbrin
(Lys236–Glu270), is involved in a salt bridge, but it is to
Lys240 in the same CH domain in utrophin. Three differ-
ent salt bridges are found at the utrophin interface
(Lys35–Asp232, Lys39–Asp229 and Lys47–Glu225).
Although the details of the interfaces differ, their shapes
are similar, reflecting their common ancestry. 
Actin-binding regions
A range of biochemical and NMR studies have identified
three potential actin-binding sites — ABS1, ABS2 and
ABS3 — within the actin-binding region of this superfam-
ily [16] (Figure 1b). ABS1 and ABS3 correspond to helix
α1 in the first and second CH domains, respectively.
These binding sites were originally identified using syn-
thetic peptides derived from dystrophin, which under-
went NMR linewidth changes upon the addition of
F-actin [22,23]. ABS2 corresponds to helices α5 and α6 in
the CH1 domain (Figure 1b). It was first identified in
ABP-120 (a Dictyostelium actin-gelation factor) by compar-
ing the ability of proteolytic fragments of ABP-120 to bind
to actin [24,25]. ABS2 was also identified in α-actinin [26]
by in vitro actin-binding studies using glutathione S-trans-
ferase (GST) fusion proteins. However, in all these
studies the ABS sequences were not part of a fully folded
domain and so residues that are not normally accessible on
the domain surface may have been able to interact with
actin. Genetic studies using Saccharomyces cerevisiae Sac6p,
a fimbrin homologue, support intersubdomain core
residues in ABS1 and ABS2 being involved in global con-
formational rearrangements [18,27].
A large body of biochemical work studying the potential
binding sites of α-actinin, dystrophin, fimbrin and filamin
on actin [23,28–35] has been more successful in identify-
ing actin subdomain 1 as an important binding site for this
class of actin-binding protein. Electron microscopic recon-
structions of actin filaments decorated with α-actinin [28]
or fimbrin [36,37] also reveal that actin subdomain 1 forms
a major site of interaction for both proteins. Both fimbrin
and α-actinin were shown to interact with adjacent actin
monomers on the long-pitch actin helix, a feature of all
F-actin-binding proteins [38].
A pseudo-atomic model of the fimbrin monomer bound to
actin was recently proposed [37] on the basis of the
fimbrin/F-actin helical reconstruction and the crystal
structures of actin and fimbrin. In this model, fimbrin
residues interacting with actin were mapped to regions in
CH1, namely helix α4, the loop from α4 to α5, and helix
α6. This is consistent with the involvement of ABS2.
Additional interaction with the N-terminal ends of both
CH domains before helix α1 were also identified such that
the start of ABS3 was also included in the molecular inter-
face. The bulk of ABS1 was, however, excluded from the
interaction with actin because of the closed conformation
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adopted by the actin-binding region of fimbrin in its
crystal structure. Hanein et al. [37] assumed that this
region did not rearrange on formation of a complex with
actin. 
The utrophin actin-binding region (residues 28–261) is a
monomer in solution and binds actin with a 1:1 stoichiom-
etry (Figure 3) [39], indicating that the utrophin crystallo-
graphic dimer cannot represent the molecular species that
binds to actin. The simplest model for the interaction of
utrophin with actin is that utrophin forms a closed-confor-
mation monomer in solution and binds actin in a similar
manner to that proposed for fimbrin [37] and α-actinin
[28]. However, the presence of the utrophin monomer in a
different conformation in the crystal raises the question of
whether this conformation is of physiological significance.
For example, it is possible that the open conformation
adopted in the crystal mimics that in which it binds to
actin, a possibility that was also suggested as an alternative
model for fimbrin binding to actin by Goldsmith et al. [18].
This would involve ABS1 and ABS3 more directly in
binding to actin. Further data from electron microscopic
reconstructions of utrophin bound to actin filaments are
required to test this proposal. Similar analyses have
already performed for fimbrin [37], α-actinin [28] and
calponin [40].
Biological implications
Utrophin is expressed ubiquitously and is localised to the
plasma membrane, where it is believed to be involved in
membrane stabilisation and organisation. This role is
facilitated by its multidomain structure, which links the
actin cytoskeleton to the extracellular matrix via its asso-
ciation with a glycoprotein complex. In particular,
utrophin has been shown to be essential in development
of fully functional neuromuscular junctions [41,42]. Dys-
trophin is a close homologue of utrophin (69% similarity
over 3500 residues) and mutations in this region of the
dystrophin locus cause Duchenne and the less severe
Becker muscular dystrophies [43]. Transgenic experi-
ments with mouse models of these disorders have shown
that increasing expression of utrophin can alleviate the
symptoms [5], suggesting that utrophin may have thera-
peutic potential for Duchenne muscular dystrophy
patients. Actin binding is localised in the first ~240 amino
acids of utrophin and dystrophin and this region seems to
be essential for function, as disease-causing mutations
are found in this region in dystrophin [44]. Homologous
actin-binding regions are found in a wide range of pro-
teins including β-spectrin, α-actinin, fimbrin and plectin. 
The structure of the actin-binding region of utrophin
consists of two calponin-homology (CH) domains, each
consisting of four main α helices. The CH domains of
two utrophin actin-binding regions interact to form an
extended head-to-tail dimer in the crystals. This is in
contrast to the homologous region of fimbrin, which
forms a tight monomer in its crystals [18]. The more
extended structure observed in the utrophin crystals sug-
gests that actin-binding region quaternary structures of
these proteins may be more dynamic than previously
thought. The more open structure allows us to speculate
that sequences previously identified by biochemical
methods as important for actin binding may be directly
involved in the interaction with the actin cytoskeleton. 
Materials and methods
Protein expression and crystallisation 
DNA encoding utrophin amino acids 28–261 was generated by the
polymerase chain reaction (PCR) from a utrophin construct encoding
residues 1–261 [1] and was inserted as an NdeI-SalI fragment into the
pET vector pSJW1 [13]. This construct was transformed into
Escherichia coli BL21(DE3) and grown at 37°C in minimal media sup-
plemented with a range of amino acids and vitamins including 50 mg l–1
selenomethionine and 100 mg l–1 ampicillin to an absorbance of
0.6–0.8 at 600 nm. 0.5 mM isopropylthiogalactoside (IPTG) was added
and the cells left to grow for 3–5 h more at 30°C. The cells were har-
vested by centrifugation and frozen. The utrophin 28–261 product was
expressed to a high level as a non-fusion protein and was mainly
soluble. Cells were lysed by treatment with lysozyme (5 mg l–1 of
culture) for 30 min at room temperature in 25% sucrose, 50 mM Tris
pH 8.0, 1 mM EDTA, 1 mM sodium azide. After centrifugation at
40,000g for 30 min, the clarified supernatant was purified by anion
exchange on CM50 (Pharmacia) equilibrated in 20 mM Tris pH 8.0 and
the protein was eluted with a linear gradient of NaCl from 0 to 0.5 M in
the same solution. Fractions pooled on the basis of sodium dodecyl sul-
phate polyacrylamide gel electrophoresis (SDS–PAGE) were subjected
to gel filtration on a column of Sephadex S200 (Pharmacia) in 20 mM
Tris pH 8.0, 100 mM NaCl. The purified protein was concentrated to
50 mg ml–1 without significant precipitation. Crystals were obtained by
vapour diffusion at 20°C against 2.0 M sodium formate (unbuffered) in
0.1 M sodium acetate pH 4.7.
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Figure 3
Actin-binding curve of the utrophin actin-binding region (residues
28–261) with rabbit skeletal muscle (F-actin). A typical binding curve
performed using the co-sedimentation assay described in [1] is shown.
The calculated binding affinity, determined by a Michaelis–Menten-type
fitting, was 67 ± 14 µM with a stoichiometry 1.29 ± 0.08
utrophin:actin, that is 1:1.
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Structure determination
Data were collected as described in Table 1. Programs used were
from the CCP4 suite [45], unless separately referenced. Data were
processed using DENZO and SCALEPACK [46]. Selenium sites
were found from the anomalous Patterson using SHELXS-90 [47]
(with F values calculated using REVISE). The six strongest sites were
used in MLPHARE to find the remaining four. A solvent-flattened map
for initial building was produced using SHARP [48] and SOLOMON
[49]. CH2 domains were built by placing the methionine sulphurs of
1BHD [13] on the selenium sites. CH1 domains were built using
bones in O [50]. Refinement from 100 to 3.0 Å was carried out using
a bulk-solvent correction in X-PLOR and rebuilding using O. 
Accession numbers
The coordinates have been deposited in the PDB database with acces-
sion code 1QAG.
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